Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


21.10.2019

1 Am J Clin Pathol
1 Ann Oncol
3 Ann Surg Oncol
1 BMC Cancer
1 Cancer
2 Cancer Sci
1 Chest
1 Clin Cancer Res
4 Clin Lung Cancer
1 Int J Cancer
1 J Cancer Res Clin Oncol
1 J Surg Oncol
3 J Thorac Cardiovasc Surg
6 J Thorac Oncol
2 Lancet Oncol
1 Lung Cancer
3 Oncogene
4 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. CAUPENA C, Esteban L, Jaen A, Barreiro B, et al
    Concordance Between Rapid On-Site Evaluation and Final Cytologic Diagnosis in Patients Undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Non-Small Cell Lung Cancer Staging.
    Am J Clin Pathol. 2019 Oct 16. pii: 5588641. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. KIM C, Liu SV
    First-line EGFR TKI therapy in Non-Small Cell Lung Cancer: Looking back before leaping forward.
    Ann Oncol. 2019 Oct 15. pii: 5587761. doi: 10.1093.
    PubMed     Text format    


    Ann Surg Oncol

  3. DENG HY, Zhou Q
    ASO Author Reflections: Lobe-Specific Lymph Node Dissection for Early-Stage Non-small Cell Lung Cancer: A Long Way to Go in the Era of Minimally Invasive Thoracic Surgery.
    Ann Surg Oncol. 2019 Oct 16. pii: 10.1245/s10434-019-07946.
    PubMed     Text format    

  4. ZHANG X, Su XD
    ASO Author Reflections: Which Is a Better Way to Describe Tumor Size of Lung Cancer: Tumor Volume or Diameter?
    Ann Surg Oncol. 2019 Oct 16. pii: 10.1245/s10434-019-07938.
    PubMed     Text format    

  5. DENG HY, Zhou J, Wang RL, Jiang R, et al
    Lobe-Specific Lymph Node Dissection for Clinical Early-Stage (cIA) Peripheral Non-small Cell Lung Cancer Patients: What and How?
    Ann Surg Oncol. 2019 Oct 15. pii: 10.1245/s10434-019-07926.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. YANG Z, Liu C, Wu H, Xie Y, et al
    CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.
    BMC Cancer. 2019;19:948.
    PubMed     Text format     Abstract available


    Cancer

  7. PRINTZ C
    First Person: Paul Bunn, Jr, MD, FASCO: An icon in the oncology world, he has led major cancer organizations and clinical trials and launched the University of Colorado Cancer Center.
    Cancer. 2019;125:9-10.
    PubMed     Text format    


    Cancer Sci

  8. FENG S, Wang H, Wang Y, Sun R, et al
    Apatinib induces 3-hydroxybutyric acid production in the liver of mice by peroxisome proliferator-activated receptor alpha activation to aid its antitumor effect.
    Cancer Sci. 2019;110:3328-3339.
    PubMed     Text format     Abstract available

  9. KENMOTSU H, Yoh K, Mori K, Ono A, et al
    Phase II study of nab-paclitaxel+carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
    Cancer Sci. 2019 Oct 13. doi: 10.1111/cas.14217.
    PubMed     Text format     Abstract available


    Chest

  10. OST DE, Niu J, Zhao H, Grosu H, et al
    Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and Diagnosis.
    Chest. 2019 Oct 11. pii: S0012-3692(19)34007-3. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  11. BLAKELY CM
    A new pathway emerges to interpret lung cancer genomic alterations.
    Clin Cancer Res. 2019 Oct 14. pii: 1078-0432.CCR-19-2861.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  12. BOVER M, Yarza R, Docampo LI
    Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm.
    Clin Lung Cancer. 2019 Aug 3. pii: S1525-7304(19)30216.
    PubMed     Text format    

  13. DAL MASO A, Lorenzi M, Roca E, Pilotto S, et al
    Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
    Clin Lung Cancer. 2019 Aug 5. pii: S1525-7304(19)30213.
    PubMed     Text format     Abstract available

  14. UPRETY D, Arjyal L, Vallatharasu Y, Bista A, et al
    Utilization of Surgery and Its Impact on Survival in Patients With Early Stage Small-cell Lung Cancer in the United States.
    Clin Lung Cancer. 2019 Aug 2. pii: S1525-7304(19)30217.
    PubMed     Text format     Abstract available

  15. CHIARI R, Ricciuti B, Landi L, Morelli AM, et al
    ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30154.
    PubMed     Text format     Abstract available


    Int J Cancer

  16. YANG S, Tang D, Zhao YC, Liu H, et al
    Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with non-small cell lung cancer survival.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32739.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  17. SAAD M, Lee IH, Choi TS
    Are shape morphologies associated with survival? A potential shape-based biomarker predicting survival in lung cancer.
    J Cancer Res Clin Oncol. 2019 Oct 16. pii: 10.1007/s00432-019-03048.
    PubMed     Text format     Abstract available


    J Surg Oncol

  18. YIN J, Zhao M, Lu T, Huang Y, et al
    Non-lung cancer specific mortality after lobectomy or sublobectomy in patients with stage IA non-small cell lung cancer </=2 cm: A propensity score analysis.
    J Surg Oncol. 2019 Oct 10. doi: 10.1002/jso.25724.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  19. TAYLOR M, Okereke I
    Commentary: Is radiation needed after resecting an early-stage small cell lung cancer?
    J Thorac Cardiovasc Surg. 2019 Sep 20. pii: S0022-5223(19)31888.
    PubMed     Text format    

  20. RAMAN V, Jawitz OK, Yang CJ, Voigt SL, et al
    Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 Sep 9. pii: S0022-5223(19)31760.
    PubMed     Text format     Abstract available

  21. PANI E, Kennedy G, Zheng X, Ukert B, et al
    Factors associated with nodal metastasis in 2-centimeter or less non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 Aug 25. pii: S0022-5223(19)31643.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  22. BROWN H, Vansteenkiste J, Nakagawa K, Cobo M, et al
    Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334.
    PubMed     Text format     Abstract available

  23. WELSH JW, Heymach JV, Chen D, Verma V, et al
    Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33525.
    PubMed     Text format     Abstract available

  24. ZUGAZAGOITIA J, Liu Y, Toki M, McGuire J, et al
    Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33342.
    PubMed     Text format     Abstract available

  25. CHIH-HSIN YANG J, Cheng Y, Murakami H, Yang PC, et al
    A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33332.
    PubMed     Text format    

  26. ALMOTLAK AA, Farooqui M, Siegfried JM
    Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic anti-tumor effects in non-small cell lung cancer.
    J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33523.
    PubMed     Text format     Abstract available

  27. HAN D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, et al
    New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.
    J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521.
    PubMed     Text format     Abstract available


    Lancet Oncol

  28. ANOTA A, Westeel V
    Quality of life with durvalumab in stage III non-small-cell lung cancer.
    Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30643.
    PubMed     Text format    

  29. HUI R, Ozguroglu M, Villegas A, Daniel D, et al
    Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30519.
    PubMed     Text format     Abstract available


    Lung Cancer

  30. STAMATIS G, Leschber G, Schwarz B, Brintrup DL, et al
    Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2cm, stage IA (7th edition of TNM staging
    Lung Cancer. 2019;138:19-26.
    PubMed     Text format     Abstract available


    Oncogene

  31. BLIJLEVENS M, van der Meulen-Muileman IH, de Menezes RX, Smit EF, et al
    High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome.
    Oncogene. 2019;38:4142-4153.
    PubMed     Text format     Abstract available

  32. TEW BY, Legendre C, Gooden GC, Johnson KN, et al
    Isolation and characterization of patient-derived CNS metastasis-associated stromal cell lines.
    Oncogene. 2019;38:4002-4014.
    PubMed     Text format     Abstract available

  33. ROSENFELD YB, Krumbein M, Yeffet A, Schiffmann N, et al
    VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice.
    Oncogene. 2019;38:4169-4181.
    PubMed     Text format     Abstract available


    PLoS One

  34. CIERESZKO A, Dietrich MA, Slowinska M, Nynca J, et al
    Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach.
    PLoS One. 2019;14:e0223840.
    PubMed     Text format     Abstract available

  35. DUNCAN DJ, Vandenberghe ME, Scott MLJ, Barker C, et al
    Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.
    PLoS One. 2019;14:e0223926.
    PubMed     Text format     Abstract available

  36. ZHANG P, He D, Song E, Jiang M, et al
    Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
    PLoS One. 2019;14:e0223760.
    PubMed     Text format     Abstract available

  37. GANEM J, Thureau S, Gouel P, Dubray B, et al
    Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
    PLoS One. 2019;14:e0222885.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  38. LAZARO S, Perez-Crespo M, Lorz C, Bernardini A, et al
    Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes.
    Proc Natl Acad Sci U S A. 2019 Oct 14. pii: 1821745116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: